A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes].

Trial Profile

A Randomised, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes].

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Clopidogrel (Primary) ; Ticagrelor (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PLATO
  • Sponsors AstraZeneca
  • Most Recent Events

    • 16 Nov 2016 Results (n=5135) assessing Osteoprotegerin association With major bleeding and cardiovascular outcomes presented at the 89th Annual Scientific Sessions of the American Heart Association
    • 01 Jul 2016 Results of subgroup analysis (n=4020) published in the American Heart Journal
    • 18 May 2016 Results (pooled analysis of DISPERSE-2 and PLATO PK substudy, n = 6990) assessing population pharmacokinetics of ticagrelor published in the International Journal of Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top